Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Chidamide combined with immunotherapy and chemotherapy as second-line treatment for advanced metastatic gastric cancer
ChiCTR2300077868Phase 4Not yet recruiting
- Sponsor
- Affiliated Hospital of Jiangnan University
- Start
- Dec 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of tucidinostat, tislelizumab and cadonilimab in gastric cancer (GC) and gastroesophageal junction adenocarcinoma (2 arms), sponsored by Affiliated Hospital of Jiangnan University. Primary endpoint: Objective response rate. Planned start Dec 2023; status: not yet recruiting.
02
Drugs
tucidinostattislelizumabcadonilimab
03
Conditions
gastric cancer (GC)gastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on ChiCTR2300077868.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300077868.